The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,

All the evidence gathered from the five-year trial will be used to demonstrate the long-term effect of weight loss medication. Those behind the study say the results could help develop the care pathways set by health services for treating people with obesity.

The Government is considering using drugs to help get obese people back to work - but they can lead to serious health complications

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with weight-loss treatment giant, Eli Lilly.

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy.

Eli Lilly, the US pharmaceutical giant behind weight-loss drugs like Zepbound and Mounjaro, has announced a strategic partnership with the UK government to tackle significant health challenges, particularly obesity.

The UK plans to test US firm Eli Lilly' s weight loss jab Mounjaro to help the burden on the national healthcare system. Over a quarter of UK adults suffered from obesity in 2023 according to government data.